25 June 2021 (Friday) - Myeloma

The nice people at the American Society of Hematology sent their update today. Focussing on myeloma it was rather clinical in outlook, but it is all useful stuff…

Here are the highlights in multiple myeloma:
Does Rheumatic Disease Increase Risk of MGUS Progression to Hematologic Malignancies?
Patients with MGUS and concomitant non-antibody–mediated inflammatory rheumatic diseases are at increased risk of progression to overt multiple myeloma, compared with patients who have MGUS without associated rheumatic diseases.
Older Patients With Myeloma May Have Suboptimal Response to COVID-19 Vaccination
These patients experienced reduced efficacy with Pfizer/BioNTech’s COVID-19 vaccine. However, certain factors identified patients who had a higher probability of immune response to vaccination, such as normalized immunoglobulins.
Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma
Treatment with idecabtagene ciloleucel showed encouraging efficacy in patients with heavily pretreated relapsed and/or refractory multiple myeloma, according to results from the phase II KarMMa study.

No comments:

Post a Comment